ESTRO 2025 - Abstract Book

S1069

Clinical – Head & neck

ESTRO 2025

3218

Digital Poster Influence of testosterone supplementation on HPV-positive oropharyngeal squamous cell carcinoma outcomes after radiotherapy Andres L Frias 1 , Daniel K Ebner 1 , Adam C Amundson 1 , Ashish V Chintakuntlawar 2 , David M Routman 1 , Daniel J Ma 1 1 Department of Radiation Oncology, Mayo Clinic, Rochester, USA. 2 Department of Medical Oncology, Mayo Clinic, Rochester, USA Purpose/Objective: HPV-positive oropharyngeal squamous cell carcinoma (HPV + OPSCC) incidence is continuing to increase, with males at higher overall risk 1 . Androgen receptor (AR) expression is involved in squamous cell differentiation 2 and HPV+OPSCC 3 , but limited literature has examined the relationship between testosterone exposure and outcomes. Here, the influence of testosterone supplementation on HPV+OPSCC is evaluated in a single-institution cohort. Material/Methods: Chart review of patients with HPV + OPSCC and a history of testosterone supplementation was performed using a single large academic institution tumor registry, supplemented with note evaluation performed by a registry integrated installation of Gemini 1.5 (Alphabet) and subsequent manual review. Progression-free survival (PFS) and overall survival (OS) were evaluated using Kaplan-Meier survival analysis starting from completion of radiotherapy, with Log Rank test to assess significance, using SPSS V28. Results: 133 HPV + OPSCC patient records with median follow-up of 58 months were extracted: 31 patients with a history of testosterone supplementation, and 102 patients with no receipt of testosterone therapy identified as comparative cohort. 5-year PFS for HPV + OPSCC receiving and not receiving testosterone therapy was 79.0% and 85.9%, respectively. 5-year OS was 93.3% and 88.8%, respectively. Log rank (Mantel-Cox) tests for PFS and OS revealed p = 0.13 and p = 0.76, respectively. Conclusion: LLM-enhanced registry review successfully identified a cohort of HPV + OPSCC patients receiving (or not) testosterone supplementation. Despite AR expression in HPV + OPSCC, no significant impact was found on progression-free or overall survival, potentially owing to sample size or competing risks underlying supplementation. Further analysis is forthcoming.

Keywords: testosterone, HPVOPSCC, LLM

References: 1. Lechner, M., Liu, J., Masterson, L. et al. HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol 19, 306–327 (2022) 2. Matsumoto T, Suzuki T, Nakamura M, et al. Androgen promotes squamous differentiation of atypical cells in cervical intraepithelial neoplasia via an ELF3-dependent pathway. Cancer Med. (2023) 3. Mohamed, H., Aro, K., Jouhi, L. et al. Expression of hormone receptors in oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 275, 1289–1300 (2018)